内分泌治疗对绝经后乳腺癌患者血脂和骨骼健康的影响

Abstract
Figure/Table
References (15)
Related Citation (12)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the influence of endocrine therapy on blood lipids and bone health in postmenopausal women with breast cancer.Methods A total of 105 cases of postmenopausal breast cancer patients admitted to our hospital from April 2016 to April 2017 were selected as the research objects.All patients were randomly divided into groups A,group B,group C,with 35 cases in each group.Group A was given Letrozole and Anastrozole,group B was treated with Exemestane,and group C was treated with Tamoxifen.The changes of blood lipid level and bone mineral density (BMD)were compared between the three groups before treatment and 12 months after treatment.Results The levels of total cholesterol(TC),triacylglycerol(TG),high density lipoprotein cholesterol(HDL-C),and low density lipoprotein cholesterol(LDL-C)in group A and group B were higher than those before treatment,with significant difference (P＜0.05).The levels of TC and LDL-c after treatment in group C were lower than those before treatment,and the levels of TG and HDL-C after treatment in group C were higher than those before treatment,with significant difference(P＜0.05).The level of TC after treatment in group A was higher than that in group B and group C,with significant difference (P＜0.05).The levels of TC and LDL-C after treatment in group C were lower than those in group A and group B,with significant difference (P＜0.05).The BMD of the lumbar spine and left hip after treatment in the three groups were lower than those before treatment,with significant difference (P＜0.05).The BMD of the lumbar spine and left hip after treatment in group C were higher than those in group B and group A,with significant difference(P＜0.05).Conclusion Letrozole,Analtriazole,Etoxetin,and Tamoxifen are all effective drugs for adjuvant endocrine therapy in postmenopausal breast cancer patients,but Tamoxifen is superior to the other three drugs in blood lipids and BMD.

Key words： Tamoxifen Anastrozole Breast neoplasms Blood lipids Bone mineral density

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qin
	LI De-jun
	WU Yu-ping

Cite this article:

WANG Qin,LI De-jun,WU Yu-ping. Influence of endocrine therapy on blood lipids and bone health in postmenopausal women with breast cancer[J]. 中国当代医药, 2018, 25(29): 46-48.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I29/46

[1]	叶敏欢，邓琦.阿那曲唑辅助治疗对绝经后乳腺癌患者血脂代谢的影响[J].实用癌症杂志，2017，32（2）：308-310.
[2]	童刚领，程勃然，陈晓秋，等.阿那曲唑和他莫昔芬对绝经后激素受体阳性转移性乳腺癌患者的疗效及肿瘤相关炎性因子的影响对比[J].广西医学，2018，40（1）：4-6.
[3]	李琼，柴辰，宋晖，等.乳癌术后化裁方对绝经后乳腺癌患者内分泌治疗引起骨丢失的干预作用[J].湖北中医药大学学报，2017，19（3）：13-16.
[4]	易哲福，朱碧荣.阿那曲唑对乳腺癌术后化疗患者血脂、肝功能及安全性的影响[J].解放军医药杂志，2016，28（8）：72-76.
[5]	范爱国，孙雅莹，杨国兴.来曲唑与三苯氧胺对绝经后期乳腺癌新辅助内分泌治疗的疗效观察[J].检验医学与临床，2017，14（24）：3644-3646.
[6]	杜娟，赵秀莉，张文周.280例乳腺癌患者内分泌治疗用药依从性分析[J].中国药房，2016，27（26）：3718-3720.
[7]	郭德阳，陈雷，王劲松，等.芳香化酶抑制剂用于绝经后激素依赖性乳腺癌患者新辅助内分泌治疗效果的Meta分析[J].第三军医大学学报，2016，38（7）：781-786.
[8]	蒋燕.唑来膦酸治疗绝经后乳腺癌患者骨质疏松的临床疗效和安全性[J].实用癌症杂志，2016，31（12）：2057-2059.
[9]	宋亚琪，牛凤玲，林婷，等.戈舍瑞林联合芳香化酶抑制剂对绝经前转移性乳腺癌患者骨密度的影响[J].实用临床医药杂志，2016，20（13）：56-58.
[10]	孔令泉，李欣，厉红元，等.关注乳腺癌患者血脂异常的诊断与防治[J].中华内分泌外科杂志，2017，11（2）：89-91.
[11]	胡刚，湛汇，胡如进.内分泌治疗不良反应与绝经前乳腺癌患者预后的相关性研究[J].山西医药杂志，2016，45（9）：1007-1010.
[12]	孙启慧，罗东林，田武国，等.他莫昔芬与芳香化酶抑制剂治疗乳腺癌的临床研究进展[J].解放军药学学报，2016，32（1）：69-73.
[13]	杨梅.他莫昔芬与来曲唑在绝经后乳腺癌辅助内分泌治疗中临床对比研究[J].海南医学院学报，2016，22（9）：910-912.
[14]	夏英鹏，王辉.唑来膦酸（密固达）治疗绝经后无骨转移乳腺癌患者骨质疏松的效果观察[J].中国骨质疏松杂志，2015，21（4）：463-466.
[15]	李旭，邹文静，韩丕华，等.芳香化酶抑制剂对绝经后乳腺癌患者骨密度影响临床研究[J].陕西医学杂志，2017，46（3）：393-394.